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httpcense.Abstract Paraneoplastic cerebellar degeneration (PCD) is a type of paraneoplastic neurological
disorder (PND) that is associated with many solid tumors, Hodgkin’s lymphoma (HL) and very
rarely with non-Hodgkin’s lymphoma (NHL). We report a case of PCD associated with gastric dif-
fuse large B-cell lymphoma (DLBCL) in a patient who presented with acute onset of giddiness and
double vision and had complete remission of the gastric lesion and marked improvement of cere-
bellar syndrome with rituximab-based combination chemotherapy. A brief review of the literature
is also presented.
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Paraneoplastic cerebellar degeneration (PCD) and other forms
of paraneoplastic neurological disorders (PNDs) have been de-
scribed in association with many solid tumors (like small-cell
lung cancer and adenocarcinoma of the breast and ovary),
Hodgkin’s lymphoma (HL) and very rarely with non-
Hodgkin’s lymphoma (NHL) [1]. Symptoms of neurological
disturbance may precede those of the underlying malignancy.
We report a patient who presented with rapidly progressive
pan-cerebellar syndrome with encephalopathy and was
subsequently diagnosed to have gastric diffuse large B-cell
lymphoma (DLBCL). It is a clinical challenge to diagnose suchational Cancer Institute, Cairo University.
.001
232 K.C. Lakshmaiah et al.a rare presentation of a neoplastic condition. There are no spe-
ciﬁc therapies for PCD described [2].
Case history
A 68-year-old male presented with a two month history of pro-
gressive unsteadiness while walking, tendency to fall to either
side, and slurred speech. He had lost about 5 kg of weight in
the last 2 months. This was followed by altered behaviour with
fearfulness and talking to self for last four days. Patient had
progressive difﬁculty in walking due to gait ataxia and postural
instability and required support for ambulation. There were no
other systemic or neurological symptoms during this period.
There was no signiﬁcant past medical history. Examination re-
vealed titubation, upbeat nystagmus, truncal and gait ataxia,
bilateral limb ataxia, normal sensory examination, brisk deep
tendon reﬂexes and ﬂexor plantar response. He was noted to
have ﬂuctuating sensorium, with multifocal rest and action in-
duced myoclonus of limbs and facial muscles. He developed
signiﬁcant worsening of behavioural disturbances during eval-
uation in hospital with visual hallucinations, and disturbed
sleep.
He was evaluated for subacute onset pan-cerebellar
syndrome with encephalopathy; the differential diagnoses
considered included paraneoplastic or non-paraneoplastic
autoimmune encephalopathy, neurosyphilis, intracranial space
occupying lesion, and Creuzfeldt Jakob disease. Investigations
for the same were carried out. Routine investigations including
haemogram, renal and hepatic function tests, serum electro-
lytes, serum ammonia (27.8; ref: 11–35 lmol/l) and lactate
(12.7; ref: 4.5–20 mg/dl) were normal. Thyroid function tests
were normal [T3: 83.8, (ref: 71–178 ng/dl); T4: 8.42, (ref: 4.5–
12.5 lg/dl); TSH: 1.17, (ref: 0.4–5.5 lIU/ml)], anti thyroid per-
oxidase antibody was borderline (35.9; ref: upto 34 IU/ml),Figure 1 Whole body PET–CT showing stomach wall thickenand serum sample was negative for human immunodeﬁciency
virus (HIV) antibodies and Venereal Disease Research Labo-
ratory (VDRL) test. Magnetic resonance imaging of the brain
including diffusion weighted imaging (DWI) and apparent dif-
fusion coefﬁcient (ADC) and electroencephalogram (EEG)
were unremarkable. Routine analysis of the cerebrospinal ﬂuid
(CSF) showed 10 cells (9 lymphocytes, 1 polymorph), normal
protein and glucose. Repeated CSF cytospin failed to yield
any neoplastic cells. Since the above investigations did not pro-
vide a clue to the diagnosis, he was evaluated further for pos-
sible paraneoplastic aetiology in view of rapidly progressing
symptoms. Stool occult blood was positive, while serological
markers for paraneoplastic cerebellar degeneration including
anti-Yo, anti-Hu, anti-Tr, anti-Ma and anti-Ri antibodies were
all negative. Antibodies for autoimmune encephalopathy like
N-methyl D-aspartate (NMDA) and LGI-1 were not tested.
Whole body positron emission tomography (PET)–com-
puted tomography (CT) scan performed using 10 mCi of intra-
venous ﬂuorodeoxyglucose (FDG) showed a 2.3 · 1.8 cm
metabolically active focal mural thickening of the gastric fun-
dus and two small pulmonary nodules in the left lower lobe
and the right middle lobe measuring 4 and 3 mm in diameter,
respectively (Fig. 1). Upper gastrointestinal endoscopy showed
an elevated lesion with surface ulceration in the gastric fundus
(Fig. 2A). Histopathology of the lesion showed gastric mucosa
effaced with sheets of large mononuclear lymphoid cells with
scant cytoplasm and vesiculated nuclei with prominent nucle-
oli. The cells were CD20 positive, cytokeratin (CK) negative,
and CD3 negative, suggestive of DLBCL of the stomach
(Fig. 2B and C).
Colonoscopy and bone marrow aspiration were non-con-
tributory. A diagnosis of gastric DLBCL stage IV (pulmonary
metastases) with an International Prognostic Index (IPI) score
of 4/5 and PCD and limbic encephalopathy was thus made. Heing (A) and areas with increased metabolic activity (B–D).
Figure 2 Gastroscopy showing elevated lesion with ulceration (A), Hematoxylin and eosin (H&E) stain of the stomach showing large B
cells within the glandular structure (B) and immunochemistry (IHC) showing CD20 positive cells (C).
Table 1 Paraneoplastic neurological disorder (PND) classiﬁ-
cation by site [2].
1. PND aﬀecting the central nervous system
Subacute cerebellar degeneration
Opsoclonus–myoclonus
Encephalomyelitis
Limbic encephalitis
2. PND aﬀecting the peripheral nervous system
Autonomic neuropathies
Subacute sensory neuronopathy
3. PND aﬀecting the neuromuscular junctions and muscles
Lambert-Eaton syndrome
Dermatomyositis
Myasthenia gravis
Table 2 Auto-antibodies seen in paraneoplastic cerebellar
degeneration (PCD) associated with speciﬁc cancers [13].
Antibodies Associated cancer
Anti-Hu Small-cell lung cancer (SCLC)
Anti-Ri Breast, gynaecological, SCLC
Anti-Tr Hodgkin’s lymphoma
Anti-yo Ovarian, breast
Anti-CRMP5/CV2 SCLC, thymoma, gynaecological
Anti-mGluR1 Hodgkin’s lymphoma
Anti-VGCC SCLC
Anti-Ma Many
Anti-Ta/Ma2 Testis
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for 5 days) for PND. There was a signiﬁcant improvement in
encephalopathy (although cerebellar features persisted) and
he was referred for management of DLBCL.
He subsequently received combination chemotherapy for
gastric DLBCL with rituximab, cyclophosphamide, doxorubi-
cin, vincristine and prednisolone (R-CHOP). Interim assess-
ment of the disease status at the end of three cycles showed
partial response. Major resolution of neurological symptoms
was observed after the 3rd cycle of chemotherapy and maxi-
mum improvement was seen two weeks after the completion
of 6 cycles of R-CHOP. The patient developed syndrome of
inappropriate anti-diuretic hormone secretion (SIADH) after
second cycle of R-CHOP which was successfully managed
according to institutional protocol. He was also treated with
six courses of intrathecal methotrexate, hydrocortisone and
cytarabine. At 8 month follow-up, the gastric lesion was in
complete remission and there was a signiﬁcant improvement
in cerebellar signs. He is currently on regular follow up.
Discussion
Paraneoplastic syndromes (PS) are remote manifestations of a
malignancy not caused by the local effects of compression,
inﬁltration or metastases, but are likely to be due to ectopic
production of hormones, antibodies or cytokines [1]. PS has
protean manifestations, and may involve the neurological,
endocrine, haematological, renal, cutaneous, or other systems,
or a combination of these. PND may result in a wide spectrum
of disorders of the central nervous system, peripheral nerves,
neuromuscular junctions, or muscles (Table 1) [3]. PCD is
the most common PND, accounting for about 36% cases [4].
Several salient features in our patient are worth highlight-
ing. Firstly, the association of PS with NHL is quite uncom-
mon (though not unknown) compared to pulmonary, breast
and gynaecological tumors. Moreover, the association of
PND with gastric DLBCL is rare. In general, the best charac-
terized PND with lymphomas is PCD commonly linked to
anti-Tr antibody and rarely to autoantibodies to mouse metab-
otropic glutamate receptor (mGLuR1). Our patient was
negative for auto-antibodies associated with PCD, including
anti-Tr.
Secondly, the occurrence of encephalopathy as a paraneo-
plastic manifestation of lymphoma is not common, as reported
in the case series by Briani et al. [5]. However, paraneoplastic
limbic encephalitis associated with antibodies to NMDAreceptor as well as without an identiﬁed autoantibody have
been reported in association with HL [6,7].
Finally, our patient presented with rapidly progressive
encephalopathy on the background of a pan-cerebellar syn-
drome, and evaluation for other aetiologies of encephalopathy
including structural, metabolic and infectious causes was neg-
ative. Antibodies for NMDA and mGLuR1 receptor could not
be carried out in this patient. Since his encephalopathy im-
proved with intravenous steroids; it can be indirectly inferred
that it was an immune-mediated paraneoplastic manifestation
of his gastric malignancy.
In patients with PCD, speciﬁc auto-antibodies may be asso-
ciated with the underlying malignancy (Table 2). The progno-
sis of PND is variable and the response to immunotherapy is
Table 3 Overview of previously reported cases of PCD with non-Hodgkin’s lymphoma.
Age (Yrs) Cell type
(B or T)
Histology Stage Lymphoma
speciﬁc therapy
Response of
lymphoma
Response
of PCD
symptoms
Outcome Reference
55 Not identiﬁed NA I Radiation CR Partially improved Alive Graus et al. [3]
72 Not identiﬁed NA II COP CR Stable Alive Albert et al. [17]
53 T cell NHL IV COP PD Worsened Dead Clouston et al. [18]
42 T cell NHL III ACOMPB CR Worsened Dead Symonds et al. [19]
28 T cell ALCL III CHOP CR Worsened Dead Ang et al. [20]
47 Composite
(HL and NHL)
NA II ABVD+
rituximab
CR Partially improved Alive Ishihara et al. [21]
68 B cell DLBCL NA NA CR Worsened Dead Rodis et al. [22]
55 B cell FL IV R-CHOP CR Improved Alive Shimazu et al. [14]
(Case series n= 5)
50–70
All 5 were B-cell
lymphomas
Not known NA -NA NA None improved 2 of 5 died Briani et al. [5]
68 B cell DLBCL-stomach IV R-CHOP CR Improved Alive Present case
Abbreviations: ABVD: adriamycin, bleomycin, vinblastine, dacarbazine; ACOMPB: adriamycin, cyclophosphamide, vincristine (oncovin)
methotrexate, prednisolone and bleomycin; ALCL: anaplastic large cell lymphoma; CHOP: rituximab, cyclophosphamide, vincristine (oncovin),
prednisolone; COP: cyclophosphamide, vincristine (oncovin), prednisolone; CR: complete remission; DLBCL: diffuse large B-cell lymphoma;
FL: follicular lymphoma; HL: Hodgkin’s lymphoma; NA: not available; NHL: non-Hodgkin’s lymphoma; PCD: paraneoplastic cerebellar
degeneration; PD: progressive disease; R-CHOP: rituximab, cyclophosphamide, vincristine (oncovin), prednisolone.
234 K.C. Lakshmaiah et al.unsatisfactory notwithstanding the fact that these are immune
mediated disorders. The type of antibody present in a patient
may predict neurological recovery. Auto-antibodies may be di-
rected against intracellular antigens (like anti-Hu, anti CV2,
anti-amphiphysin, anti-Ri, anti-Yo, and anti-MA2) or neuro-
nal surface antigens (like voltage-gated potassium channels
(VGKC), NMDA receptor, and mGluR1). The former are
possibly the result of T-cell mediated immune response and lat-
ter are likely due to humoral immune response [8,9]. It has
been observed that in general neurological recovery is better
with conditions having antibodies against neuronal surface
antigens. Additionally, patients with PCD associated with
anti-Hu or anti-Yo antibodies are less likely to recover, while
those with anti-Tr, anti-Ri, or anti-CV2 antibodies have a bet-
ter probability of neurologic improvement [10,5,11]. In addi-
tion to cancer per se, other poor prognostic factors for PCD
are old age and other neurological co-morbidities [12].
Autoimmunity in PND targeting intracellular antigens is a
T-cell immune mediated response and hence therapy with con-
ventional immunomodulatory agents that target humoral
immunity may not affect the pathogenetic mechanisms [8,9].
Rituximab, an important therapeutic agent in the management
of B-cell lymphoma, is being increasingly used in the treatment
of autoimmune disorders [12,13]. It has been postulated that
rituximab leads to a decrease in the number of B cells and con-
sequently reduced secretion of autoantibodies both in serum
and CSF, thereby helping in resolution of PND by unknown
mechanisms [4].
Briani et al. have reported a series of 29 NHL patients who
displayed symptoms of PND, of whom 5 were diagnosed to
have PCD. Three out of these 5 patients were positive for
auto-antibodies, and none of them had neurological improve-
ment with therapy [5]. Apart from this case series, eight indi-
vidual cases of NHL have been reported to be associated
with PCD [3,14,17–22]. Key features of these reports are sum-
marized in Table 3.
Among the reported NHL cases, the paraneoplastic anti-
body was identiﬁed in only one case of composite lymphoma
and it is not clear whether there are speciﬁc antibodies forPNS associated with NHL [13]. Treatment with intravenous
immunoglobulin (IvIg) has shown beneﬁt when administered
within 3 months of onset of symptoms in a series of 15 PCD
cases [15]. Some investigators have used triple intrathecal ther-
apy with cytarabine, methotrexate and steroid in addition to
IvIg and have reported recovery of PNS [16].
Conclusion
A myriad of PNDs have been described, with and without spe-
ciﬁc antibodies, and the spectrum is constantly expanding. We
have described a rare association of PCD and encephalopathy
with gastric DLBCL and reviewed the relevant literature. It is
imperative to have a high index of suspicion in order to estab-
lish early diagnosis of these rare disorders and therefore insti-
tute timely and appropriate treatment.
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